S100 A4对子宫内膜癌细胞顺铂化疗敏感性影响分析

目的分析靶向沉默S100A4基因对子宫内膜癌细胞顺铂化疗敏感性的影响。方法病毒转染子宫内膜癌KLE细胞株并获得稳定细胞株;聚合酶链反应检测转染后子宫内膜癌细胞中S100A4 mRNA的表达;Western blot印迹法检测转染后子宫内膜癌细胞中S100A4蛋白的表达水平;CCK8法检测转染后子宫内膜癌细胞的增殖变化。结果阴性对照组、shRNA干扰实验组、过表达实验组3组之间光密度值两两比较,差异均有统计学意义(P<0.05)。阴性对照组、shRNA干扰实验组、过表达实验组的S100A4相对表达水平两两比较,差异均有统计学意义(P<0.05)。空白对照组、shRNA干扰实验组的S100A4蛋白表达水平明显低于阴性对照组,过表达实验组的S100A4蛋白表达水平明显高于阴性对照组,差异均有统计学意义(P<0.05)。空白对照组、阴性对照组、shRNA干扰实验组、过表达实验组的IC50值两两比较,差异均有统计学意义(P<0.05)。结论靶向沉默S100A4基因可抑制肿瘤细胞增殖,促进细胞凋亡,增强子宫内膜癌细胞对顺铂的敏感性。     

pcDNA3.1(-)/PSMA7真核表达质粒的构建及其在A549细胞中的表达

目的 构建pcDNA3.1(-)/PSMA7真核表达质粒并建立人肺腺癌细胞株A549的稳定表达株.方法 采用RT-PCR法从正常人支气管上皮细胞株HBE135-E6E7中克隆得到PSMA7 cDNA全长序列,将之与pMD18-T载体连接.双酶切和测序鉴定后,再将PSMA7片段亚克隆到真核表达载体pcDNA3.1(-)上.构建好的pcDNA3.1(-)/PSMA7真核表达质粒经双酶切和测序鉴定后,经脂质体转染法转入A549细胞株中,经CA18筛选,得到阳性克隆细胞株,再用RT-PCR及Westem blotting法检测转染后PS-MA7的mRNA及蛋白表达水平.结果 pcDNA3.1(-)/PSMA7质粒经双酶切鉴定和DNA测序证实.目的 基因PSMA7的序列完全正确,真核表达质粒构建成功.RT-PCR检测显示,转染pcDNA3.1(-)/PSMA7组的PSMA7 mRNA表达水平(2.698±0.661)明显高于未转染组(1.243±0.176)和转染pcDNA3.1(-)组(1.198±0.514,P<0.05),后两者间无明显差异.Western blotting检测同样显示,转染pcDNA3.1(-)/PSMA7组的蛋白表达水平(1.978±0.661)明显高于未转染组(0.891±0.234)和转染pcDNA3.1(-)组(0.782±0.375,P<0.05),后两组间亦无明显差异.结论 成功构建了PSMA7基因的真核表达质粒,并建立了稳定表达PSMA7的A549细胞株,为后续研究奠定了基础.     

Artemis蛋白磷酸化对紫外线C引发的复制检测点的调控

目的 研究复制叉前进受阻后Artemis蛋白S516和S645丝氨酸位点的磷酸化和对细胞周期复制检测点的影响。方法 Western-blotting检测细胞受紫外线C照射后Artemis S516和S645两个位点的磷酸化变化;突变Artemis蛋白的第516和645位氨基酸,构建非磷酸化和模拟磷酸化的突变体S516-645A和S516-645D表达质粒,转染HEK 293细胞建立稳定表达细胞系;流式细胞仪检测受UVC照射后的细胞周期,Western-blotting检测UVC照射后2、6、12 h的Chk1、γ-H2AX、Cdk2蛋白的表达变化,免疫共沉淀激酶实验检测Cdk2 IP激酶的活性。结果 Artemis蛋白S516和S645位点在UVC照射后发生迅速和持久的磷酸化,ATR是Artemis S516和S645磷酸化的主要激酶;S516-645A非磷酸化双突变导致细胞周期在S期复制检测点停留时间延长。Artemis S516-645A双突变不影响Chk1、Cdk2、γ-H2AX蛋白表达水平,却抑制了Cdk2 IP激酶的活性。结论 ATR激酶对Artemis蛋白S516和S645位点的磷酸化促进了细胞周期从UVC引发的复制检测点中恢复。     

人黑色素浓集激素1型受体真核表达载体的构建及稳定转染CHO细胞系的建立

目的 构建人黑色素浓集激素1型受体(MCHR1)真核表达载体,转染CHO细胞,建立稳定转染的CHO细胞系.方法 采用PCR方法,以人胎脑cDNA文库为模板扩增人MCHR1基因的全长cDNA编码区序列,利用DNA重组技术将其定向插入到真核表达载体pcDNA3.1( ),经酶切和测序鉴定后,用脂质体转染法转染CHO细胞,通过G418筛选,建立稳定转染的CHO细胞系,用RT-PCR、Western blot及免疫荧光法检测MCHR1的表达.结果 成功构建了pcDNA3.1( )/MCHR1真核表达载体,并建立了稳定转染的CHO细胞系,成功地表达了目的基因.结论 真核表达载体的构建和稳定转染CHO细胞系的建立为进一步研究MCHR1功能奠定了良好的实验基础.     

人HGF基因重组逆转录病毒表达载体及包装细胞株的构建和鉴定

目的 :构建携带肝细胞生长因子 (HGF)的逆转录病毒载体 ,并建立高效、稳定生产HGF的包装细胞株。方法 :以pcDNA3.0 HGF质粒为模板进行PCR反应扩增出HGF基因全长序列 ,亚克隆至逆转录病毒载体pMSCVneo构建重组逆转录病毒质粒 ,以脂质体介导转染包装细胞PT6 7,经G4 18筛选 ,进而挑选抗性集落扩大培养后 ,用靶细胞NIH3T3测定病毒滴度 ,筛选出高效产毒细胞株。扩大培养后进行RT PCR鉴定HGFmRNA的表达。扩大培养NIH3T3细胞抗性集落 (NIH3T3/HGF) ,并用细胞培养上清进行人肝癌细胞系HepG2的扩散试验。结果 :PCR反应扩增出 2 2 0 0bp的HGF基因 ,构建了重组逆转录病毒表达载体pMSCV HGF ,测序鉴定正确。经脂质体介导转染包装细胞、G4 18筛选和NIH3T3测定病毒滴度 ,筛选出具有最高病毒滴度 (8.8× 10 7cfu /ml)的细胞集落 ,扩大培养后建立高效表达HGF的包装细胞株PT/HGF ,RT PCR证实HGF基因在PT/HGF中有转录。NIH3T3/HGF培养上清可使HepG2细胞扩散 ,形态改变。结论 :成功构建了携带HGF的逆转录病毒载体pMSCV HGF ,并建立了稳定、高效生产有活性的HGF的产毒细胞株PT/HGF。     

PCGF1过表达慢病毒载体的构建及稳定过表达A549细胞系的建立

目的 构建人多梳家族环指蛋白1(PCGF1)基因的慢病毒载体,建立稳定表达PCGF1基因的细胞系.方法 根据人PCGF1序列设计并合成引物,以A549细胞cDNA为模板,PCR扩增目的基因.双酶切目的基因并插入pLVX-IRES-puro质粒,对重组质粒进行慢病毒包装,用包装好的病毒感染A549细胞系,通过嘌呤霉素筛选阳性表达细胞,Western blotting验证PCGF1表达情况.结果 重组质粒经测序分析正确,瞬时转染293T细胞后,Western blotting验证PCGF1表达明显升高.包装慢病毒颗粒后感染A549细胞,经嘌呤霉素筛选后,Western blotting验证得到PCGF1稳定过表达的A549细胞系.结论 成功构建了pLVX-IRES-PCGF1-puro慢病毒过表达载体和PCGF1稳定过表达的A549细胞系,为进一步研究PCGF1的功能奠定了基础.     

重组人α-半乳糖苷酶A在CHO细胞中的表达及鉴定

目的 构建重组人α-半乳糖苷酶A(GLA)真核表达载体,并在中华仓鼠卵巢细胞CHO中表达重组的人GLA.方法 利用RT-PCR方法从人肝癌细胞中克隆人GLA cDNA,并构建到哺乳动物细胞表达载体pcDNA3.1/myc-His A中.将重组质粒转染CHO细胞并用G418筛选.用丁酸钠诱导G418抗性细胞,检测培养上清中的GLA活性,筛选高表达GLA的细胞株.采用HisTrapTM FF纯化培养上清中的GLA蛋白并利用Western 印迹进行鉴定.结果 成功构建了哺乳动物细胞表达载体pcDNA3.1/myc-His A-GLA,并在中华仓鼠卵巢细胞CHO中表达,得到高表达量的单克隆(蛋白比活为1935 U/mg).纯化后的培养上清在50×103(Mr)附近出现单一条带,通过Western 印迹确定为GLA蛋白.结论 成功构建了真核表达载体pcDNA3.1/myc-His A-GLA,获得了具有生物活性的重组人GLA,为临床上治疗法布莱病奠定了一定基础.     

肺腺癌细胞株表皮生长因子受体突变对射线诱导的DNA修复的影响

目的 探讨肺腺癌细胞株表皮生长因子受体(EGFR)酪氨酸激酶区域突变对放射线诱导的DNA双链断裂后修复的影响。方法 对A549细胞株(wt EGFR)和H1975细胞株(mut EGFR)进行6 MV X射线照射。免疫荧光方法观察两种细胞株经4 Gy X射线照射后不同时间点细胞核中γH2AX焦点数。免疫共沉淀法检测EGFR与DNA-PKcs的结合情况。Western blot方法检测细胞核中RAD51表达以及EGFR核转运情况。结果 H1975细胞株(mut EGFR)经X射线照射后DNA双链断裂修复延缓,EGFR不进行核转运,细胞核中无EGFR-DNA-PKcs复合物形成,且不影响细胞核RAD51的表达。A549细胞株(wt EGFR)经射线诱导后EGFR发生核转运,并与DNA-PKcs结合,发挥非同源修复,同时RAD51进入细胞核,发挥同源修复作用。结论 EGFR酪氨酸激酶区突变的肺腺癌细胞株能减少X射线诱导的DNA双链断裂后非同源修复和同源修复,延缓DNA修复动力学,从而增加放射敏感性。     

S100A4 siRNA对人胰腺癌BxPc-3细胞增殖、迁移及侵袭的影响

目的观察利用小干扰RNA（small interference RNA,siRNA）技术下调人胰腺癌BxPc-3细胞中钙结合蛋白S100A4表达后对细胞增殖、迁移和侵袭的影响。方法设计合成针对S100A4的特异性siRNA,转染至人胰腺癌BxPc-3细胞,以Western印迹检测转染前后S100A4蛋白表达变化;克隆形成率实验检测转染前后BxPc-3细胞增殖能力;Transwell小室模型检测转染前后BxPc-3细胞迁移和侵袭能力变化。结果 Western印迹结果显示BxPc-3细胞转染S100A4siRNA48h后,S100A4蛋白表达明显下调;Transwell小室验证转染S100A4siRNA后细胞的迁移和侵袭能力明显降低。结论本研究结果表明,S100A4表达下调后可抑制胰腺癌细胞的增殖、迁移和侵袭,提示S100A4可以作为一个潜在的肿瘤治疗靶标。     

S100A2全长基因真核表达载体pEGFP-N2-S100A2的构建及其在胃癌细胞系BGC-823中的表达

 目的 克隆S100A2 cDNA,构建pEGFP-N2-S100A2重组表达载体,转染胃癌细胞系BGC-823,为探讨其对胃癌细胞系的影响奠定实验基础.方法 应用RT-PCR 和DNA 重组技术构建pEGFP-N2-S100A2 融合蛋白表达载体,质粒经测序正确后,用脂质体转染BGC-823 细胞.结果 重组质粒经限制性酶切鉴定得到与S100A2全长基因长度一致(294 bp) 的酶切产物; 测序分析证实,重组质粒中含有一与GenBank 上登录的S100A2基因(NM-005978) 序列完全一致的序列,表明成功地完成了表达载体的构建; 荧光显微镜下可见转染的BGC-823 细胞有绿色荧光蛋白的表达.结论 构建完成真核表达载体pEGFP-N2-S100A2,S100A2基因在BGC-823细胞内成功表达.     

Knee injury and Osteoarthritis Outcome Score (KOOS) - validation of a Swedish version

The Knee injury and Osteoarthritis Outcome Score (KOOS) is a self-administered instrument measuring outcome after knee injury at impairment, disability, and handicap level in five subscales. Reliability, validity, and responsiveness of a Swedish version was assessed in 142 patients who underwent arthroscopy because of injury to the menisci, anterior cruciate ligament, or cartilage of the knee. The clinimetric properties were found to be good and comparable to the American version of the KOOS. Comparison to the Short Form-36 and the Lysholm knee scoring scale revealed expected correlations and construct validity. Item by item, symptoms and functional limitations were compared between diagnostic groups. High responsiveness was found three months after arthroscopic partial meniscectomy for all subscales but Activities of Daily Living.     

Endovascular management of carotid-cavernous fistulas

Objective To investigate endovascular treatment of traumatic direct carotid-cavernous fistulas （CCF） and their complications such as pseudoaneurysms. Methods： Over a five-year period, 22 patients with traumatic direct CCFs were treated endovascularly in our institution. Thirteen patients were treated once with the result of CCF occluded, 8 twice and 1 three times. Treatment modalities included balloon occlusion of the CCF, sacrifice of the ipsilateral internal carotid artery with detachable balloon, coll embolization of the cavernous sinus and secondary pseudoaneurysms, and covered-stem management of the pseudoaneurysms. Results All the direct CCFs were successfully managed endovascularly. Four patients developed a pseudoaneurysm after the occlusion of the CCF with an incidence of pseudoaneurysm formation of 18.2% （4/22）. A total number of 8 patients experienced permanent occlusion of the ICA with a rate of ICA occlusion reaching 36.4% （8/22）. Followed up through telephone consultation from 6 months to 5 years, all did well with no recurrence of CCF symptoms and signs. Conclusion Traumatic direct CCFs can be successfully managed with endovascular means. The pseudoaneurysms secondary to the occlusion of the CCFs can be occluded with stent-assisted coiling and implantation of covered stents.     

The acutely limping child

Acute limping may be the result of multiple pathologies in children. The differential diagnosis varies based on the age of the child. Irrespective of age, the initial imaging work-up includes AP and frog leg radiographs of the pelvis and ultrasound; MRI may sometimes be helpful. In children less than 3 years, infections and trauma are most frequent. MRI is the imaging modality of choice when osteomyelitis is clinically suspected. Between the ages of 3 and 10 years, transient synovitis of the hip and Legg-Calvé-Perthes disease are main considerations but infection, inflammation and focal bony lesions are also considered. In children over 10 years, slipped capital femoral epiphysis also is considered.     

Do Balance Board Training Programs Reduce the Risk of Ankle Sprains in Athletes?

Introduction Ankle sprains are the most common musculo-skeletal injury that occurs in athletes,particularly in sports that require jumping and landing on one foot such as soccer,and basketball(1-4).These injuries often result in significant time loss from participation,long-term disability,and have a major impact on health care costs and resources(5-8).     

High Intensity Interval Training:New Insights

KEY POINTS ·High-intensity interval training(HIT)is characterized by repeated sessions of relatively brief，intermittent exercise.often performed with an“a11 out”effort or at an intensity close to that which elicits peak oxygen uptake(i.e.，≥90%of VO2 peak).     

Developmental validation of the PowerPlex(®) ESI 16 and PowerPlex(®) ESI 17 Systems: STR multiplexes for the new European standard

In response to the ENFSI and EDNAP groups’ call for new STR multiplexes for Europe, Promega^® developed a suite of four new DNA profiling kits. This paper describes the developmental validation study performed on the PowerPlex^® ESI 16 (European Standard Investigator 16) and the PowerPlex^® ESI 17 Systems. The PowerPlex^® ESI 16 System combines the 11 loci compatible with the UK National DNA Database^®, contained within the AmpFlSTR^® SGM Plus^® PCR Amplification Kit, with five additional loci: D2S441, D10S1248, D22S1045, D1S1656 and D12S391. The multiplex was designed to reduce the amplicon size of the loci found in the AmpFlSTR^® SGM Plus^® kit. This design facilitates increased robustness and amplification success for the loci used in the national DNA databases created in many countries, when analyzing degraded DNA samples. The PowerPlex^® ESI 17 System amplifies the same loci as the PowerPlex^® ESI 16 System, but with the addition of a primer pair for the SE33 locus. Tests were designed to address the developmental validation guidelines issued by the Scientific Working Group on DNA Analysis Methods (SWGDAM), and those of the DNA Advisory Board (DAB). Samples processed include DNA mixtures, PCR reactions spiked with inhibitors, a sensitivity series, and 306 United Kingdom donor samples to determine concordance with data generated with the AmpFlSTR^® SGM Plus^® kit. Allele frequencies from 242 white Caucasian samples collected in the United Kingdom are also presented. The PowerPlex^® ESI 16 and ESI 17 Systems are robust and sensitive tools, suitable for the analysis of forensic DNA samples. Full profiles were routinely observed with 62.5 pg of a fully heterozygous single source DNA template. This high level of sensitivity was found to impact on mixture analyses, where 54–86% of unique minor contributor alleles were routinely observed in a 1:19 mixture ratio. Improved sensitivity combined with the robustness afforded by smaller amplicons has substantially improved the quantity of data obtained from degraded samples, and the improved chemistry confers exceptional tolerance to high levels of laboratory prepared inhibitors.